Group 1: Investment and Production Capacity - Current production capacity meets expected scale, with pre-sale coverage achieved and sufficient market demand support. Expected increase in capacity utilization next year, with stable supply and cost reduction through intermediate production [2] - The company’s core product market prices: Bacillus thuringiensis raw material approximately 30,000 CNY/ton, and Pyraclostrobin raw material currently around 140,000 CNY/ton [2] Group 2: Financial Performance and Growth Drivers - Q3 performance driven by price increases of main products, improving gross profit margins [3] - Significant contribution from the sales volume of COS series pesticide products in Q3 [3] Group 3: Market Trends and Future Outlook - Short-term price stability expected for 2,4-D, with medium to long-term demand linked to the promotion of transgenic crops, leading to steady market expansion [3] - Bacillus thuringiensis market demand remains tight, with increased usage frequency driving up consumption [3] Group 4: New Product Launches - Innovative pesticide, Cyhalofop-butyl, set to launch domestically in November 2025, with domestic registration obtained in October and overseas registration in progress, expected to contribute to future growth [3] - Risk warning: Information regarding external environment assessments, company strategies, and future plans does not constitute a commitment to investors, urging rational investment and risk awareness [3]

Core Points - The company announced the conclusion of the "Research and Development Center Project" and the reallocation of surplus funds to the "Pesticide Project" [1] - The deadlines for the "Pyraclostrobin Technical Project" and "Oxathiapiprolin Technical Project" have been postponed to June 2026 [1] - The proposal requires approval from the shareholders' meeting [1]

二、主要产品的价格变动情况（不含税） | 主要产品 | 2024 年度平均售 价（元/吨） | 2023 年度平均售 价（元/吨） | 变动比率（%） | | --- | --- | --- | --- | | 杀菌剂 | 87,729.51 | 108,172.38 | -18.90 | | 杀虫剂 | 80,337.15 | 91,929.03 | -12.61 | | 其它 | 57,665.09 | 85,638.13 | -32.66 | 证券代码：605033 证券简称：美邦股份 公告编号：2025-013 陕西美邦药业集团股份有限公司 2024 年年度主要经营数据公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 根据上海证券交易所《上海证券交易所上市公司自律监管指引第3号行业信 息披露：第十三号——化工》和相关通知的要求，陕西美邦药业集团股份有限公 司（以下简称"公司"）现将2024年年度主要经营数据披露如下： 陕西美邦药业集团股份有限公司董事会 2025 年 4 月 25 日 三、主要原材料的价格变动 ...